These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Renal anemia treatment and outcome of patients with chronic kidney disease]. Kuragano T; Nakanishi T Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557 [No Abstract] [Full Text] [Related]
3. A randomized, placebo-controlled clinical trial of recombinant human erythropoietin in the anemia of prematurity. Mentzer WC; Shannon KM; Abels RI; Freeman P; Newton N; Thompson D; Phibbs RH Contrib Nephrol; 1991; 88():306-12; discussion 313. PubMed ID: 2040193 [No Abstract] [Full Text] [Related]
4. Treatment of renal anemia with recombinant erythropoietin. International workshop. Wolfenbüttle, November 22-24, 1987. Proceedings. Contrib Nephrol; 1988; 66():1-211. PubMed ID: 3391026 [No Abstract] [Full Text] [Related]
5. [Erythropoietin: its biological properties and clinical use]. Ermolenko VM; Nikolaev AIu Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979 [No Abstract] [Full Text] [Related]
6. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. Eschbach JW; Haley NR; Adamson JW Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841 [No Abstract] [Full Text] [Related]
7. [Treatment of renal anemia using human erythropoietin]. Zehnder C; Blumberg A Dtsch Med Wochenschr; 1987 Jun; 112(23):938-9. PubMed ID: 3582205 [No Abstract] [Full Text] [Related]
8. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure]. Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064 [TBL] [Abstract][Full Text] [Related]
9. Clinical application of recombinant erythropoietin in anemic cancer patients. Henry DH Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218 [TBL] [Abstract][Full Text] [Related]
10. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Macdougall IC Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379 [TBL] [Abstract][Full Text] [Related]
11. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease. Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152 [No Abstract] [Full Text] [Related]
12. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151 [No Abstract] [Full Text] [Related]
13. Serial estimation of serum interleukin 6 during treatment with recombinant human erythropoietin in patients with the anemia of rheumatoid arthritis. Jongen-Lavrencic M; Swaak AJ; Vreugdenhil G J Rheumatol; 1993 Jul; 20(7):1253-5. PubMed ID: 8371234 [No Abstract] [Full Text] [Related]